论文部分内容阅读
目的:在宫颈癌筛查中,联合应用DNA倍体分析和高危型人乳头状瘤病毒(HR-HPV)检测,为临床宫颈癌疑似病例、病理诊断有疑义病例的鉴别诊断提供一种有效的方法。方法:对239例细胞学筛查有异常的病例进行病理组织学检查,随后再次液基薄层细胞学制片、Feulgen染色,做细胞核DNA倍体分析。对有HPV感染的病例,将其检查结果与DNA倍体分析结果进行比较。结果:239例患者中114例进行了HPV检测,其中HR-HPV感染病例55例,出现异倍体69例,二者阳性检出率均与宫颈病变程度相关;HR-HPV感染病例中发现大部分有异倍体产生,二者均不受年龄影响。结论:HR-HPV感染可能导致DNA异倍体的出现,细胞核DNA倍体分析和HPV检查结果又均与病变的程度密切相关,二者联合可为疾病的筛查、预后的判断提供更多有价值的资料。
Objective: In cervical cancer screening, the combination of DNA ploidy analysis and high-risk human papilloma virus (HR-HPV) detection for clinical cervical cancer suspected cases, pathological diagnosis of suspected cases of differential diagnosis provides an effective method. Methods: 239 cases of abnormal cytology screening pathological examination, and then liquid-based thin-layer cytology, Feulgen staining, do nuclear DNA ploidy analysis. In cases of HPV infection, the results of this test were compared with those of DNA ploidy analysis. RESULTS: Of the 239 patients, 114 were tested for HPV, of which 55 were HR-HPV-infected and 69 were aneuploidy, both of which were associated with the severity of cervical lesions. Large HR-HPV infection cases were found Some aneuploidy, both are not affected by age. Conclusion: HR-HPV infection may lead to the occurrence of DNA aneuploidy, nuclear DNA ploidy analysis and HPV test results are closely related with the extent of the disease, the combination of the two can provide screening for the disease, to provide more prognostic judgment Value information.